Filing Analysis
Citius Pharmaceuticals received a formal extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company has until February 8, 2027, to maintain a closing price of at least $1.00 for ten consecutive business days to avoid delisting.
🚩 Red Flags
- Non-compliance with the Nasdaq $1.00 minimum bid price rule.
- Risk of delisting from the Nasdaq Capital Market if compliance is not met by February 8, 2027.
- Management uncertainty regarding the ability to regain compliance.
📋 Key Facts
- Received formal notice from Nasdaq on August 17, 2026, regarding a compliance deficiency.
- The deficiency relates to Nasdaq Listing Rule 5550(a)(2) (the 'Bid Price Rule').
- Nasdaq granted an extension through February 8, 2027, to evidence compliance.
- Compliance is achieved if the common stock closes at $1.00 or more for 10 consecutive business days before the deadline.
- Failure to comply by the deadline will result in a delisting notice, which the company may appeal to a Nasdaq hearings panel.
Citius Pharmaceuticals, Inc. filed an 8-K to announce its third quarter fiscal 2026 results of operations via a press release.
📋 Key Facts
- Report date: August 14, 2026
- The filing announces the release of Q3 fiscal 2026 financial results.
- Results are provided in Exhibit 99.1 as a press release.
Citius Pharmaceuticals' subsidiary, Citius Oncology, Inc., issued a press release regarding the expanding adoption of LYMPHIR® among institutional accounts. This is an informational update regarding product commercialization progress.
📋 Key Facts
- Date of report: August 5, 2026
- Subsidiary involved: Citius Oncology, Inc.
- Product mentioned: LYMPHIR®
- Content: Update on expanding base of institutional accounts ordering the product.
Citius Pharmaceuticals, Inc. filed an 8-K to report that its subsidiary, Citius Oncology, Inc., issued a press release regarding the presentation of clinical data at the Annual Meeting of the American Society of Clinical Oncology on June 1, 2026.
📋 Key Facts
- The filing date is June 1, 2026.
- The event involves the presentation of clinical data by the subsidiary Citius Oncology, Inc.
- The data was presented at the Annual Meeting of the American Society of Clinical Oncology.
- The press release is attached as Exhibit 99.1.
Citius Pharmaceuticals, Inc. announced its financial results for the second quarter of fiscal 2026 via a press release on May 15, 2026.
📋 Key Facts
- The company reported results of operations for the fiscal second quarter ended March 31, 2026.
- The filing was made under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by Leonard Mazur, Chairman and Chief Executive Officer.
Citius Pharmaceuticals amended a $3.8 million promissory note with its majority-owned subsidiary, Citius Oncology, to subordinate the debt to a new senior debt facility. The amendment extends the maturity indefinitely until 91 days after the new senior debt is repaid and introduces a voluntary conversion feature at $0.90 per share.
🚩 Red Flags
- Subordination of existing debt to new senior lenders, pushing repayment further down the priority list.
- Extension of maturity to an indefinite future date (linked to the repayment of other debt).
- Related-party transaction involving a majority-owned subsidiary.
- Elimination of previous triggers that would have required repayment upon capital raises.
📋 Key Facts
- The Promissory Note has an original principal amount of $3,800,111.
- The amendment was entered into on May 4, 2026, in connection with Citius Oncology's new equity financing and debt facility.
- The note is now subordinated to Citius Oncology's senior debt, with maturity set for 91 days after senior debt is fully paid.
- Prior maturity triggers related to capital raises, debt/equity issuances, or royalty-backed monetizations were eliminated.
- A voluntary conversion feature was added allowing the Company to convert principal into common stock at $0.90 per share.
- Cash prepayment of the note is prohibited prior to the new maturity date.
Citius Pharmaceuticals reported the closing of a registered direct offering and concurrent private placement of warrants, while simultaneously announcing the first commercial shipment of LYMPHIR™ to Europe by its majority-owned subsidiary.
🚩 Red Flags
- Potential for significant dilution due to the issuance of common warrants and placement agent warrants.
- Complexity arising from the majority-owned subsidiary structure (CTOR) which may impact the parent company's cash flow and valuation.
📋 Key Facts
- Closed a registered direct offering and concurrent private placement of common stock and warrants on April 23, 2026.
- The offering included pre-funded warrants, common warrants, and placement agent warrants.
- Majority-owned subsidiary Citius Oncology, Inc. (Nasdaq: CTOR) initiated the first shipment of LYMPHIR™ (denileukin diftitox-cxdl) to Europe on April 29, 2026.
- The European distribution is being handled through regional distribution partners.
Citius Pharmaceuticals entered into a securities purchase agreement to raise approximately $5.0 million through a registered direct offering and concurrent private placement. The offering includes common stock and warrants, with proceeds intended to support the commercialization of LYMPHIR™ and other corporate initiatives.
🚩 Red Flags
- Significant potential dilution from the issuance of over 5 million warrants in addition to the common stock.
- The common warrant exercise price of $0.86 is lower than the offering price of $0.985.
- Short-term lock-up period of only 45 days regarding future securities issuances.
📋 Key Facts
- The company sold 4,730,457 shares of common stock and 345,686 pre-funded warrants.
- Offering price was $0.985 per share and $0.9849 per pre-funded warrant.
- Concurrent private placement of 5,076,143 common warrants with an exercise price of $0.86 per share.
- Gross proceeds of approximately $5.0 million; net proceeds estimated at $4.5 million.
- H.C. Wainwright & Co. acted as placement agent, receiving a 7.0% cash fee and 355,330 placement agent warrants.
- Proceeds are allocated for LYMPHIR™ commercialization, milestone payments, and general corporate purposes.
Citius Pharmaceuticals, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on April 6, 2026. Shareholders elected seven directors to one-year terms and ratified the company's independent auditor for the fiscal year ending September 30, 2026.
🚩 Red Flags
- High level of broker non-votes (6,660,992) compared to votes cast for directors (approx. 2.4M), which may indicate a highly fragmented retail shareholder base with low voting participation.
📋 Key Facts
- The Annual Meeting was held on April 6, 2026.
- Seven directors were elected: Leonard Mazur, Myron Holubiak, Suren Dutia, Dr. Eugene Holuka, Dennis M. McGrath, Robert Smith, and Carol Webb.
- Wolf & Company, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending September 30, 2026.
- The auditor ratification received 8,593,946 'For' votes, while director elections saw 'For' votes ranging from 2,311,462 to 2,485,904.
- A significant number of broker non-votes (6,660,992) were recorded for the director election proposals.
Citius Pharmaceuticals announced that its majority-owned subsidiary, Citius Oncology, Inc. (Nasdaq: CTOR), issued a commercial update on March 31, 2026, regarding the U.S. launch of its drug LYMPHIR™ (denileukin diftitox-cxdl).
📋 Key Facts
- The filing reports a commercial update for LYMPHIR™ (denileukin diftitox-cxdl).
- The update was issued by Citius Oncology, Inc. (CTOR), which is a majority-owned subsidiary of Citius Pharmaceuticals (CTXR).
- The event was disclosed under Item 8.01 (Other Events) on March 31, 2026.
- A press release detailing the launch progress was included as Exhibit 99.1.
Citius Pharmaceuticals' majority-owned subsidiary, Citius Oncology (CTOR), announced positive topline results from a Phase 1 clinical trial evaluating LYMPHIR™ in combination with KEYTRUDA®.
📋 Key Facts
- The Phase 1 trial was investigator-initiated and conducted by University of Pittsburgh investigators.
- The study evaluated LYMPHIR™ (denileukin diftitox-cxdl) in combination with pembrolizumab (KEYTRUDA®).
- The trial targeted patients with recurrent or refractory gynecologic cancers, specifically ovarian and endometrial malignancies.
- The study focused on the direct T-regulatory (Treg) cell depletion activity of the combination therapy.
Citius Pharmaceuticals' majority-owned subsidiary, Citius Oncology, reported positive topline safety and efficacy results from an investigator-initiated Phase 1 trial of LYMPHIR™. The study evaluated the drug's performance when administered before CAR T therapy in patients with high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
📋 Key Facts
- Announcement date: March 4, 2026
- Subsidiary: Citius Oncology, Inc. (Nasdaq: CTOR), which is majority-owned by Citius Pharmaceuticals
- Drug: LYMPHIR™ (E7777, denileukin diftitox cxdl)
- Trial Type: Investigator-initiated Phase 1 trial
- Patient Population: High-risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)
- Clinical Context: LYMPHIR™ was administered prior to commercial CD19 directed CAR T therapy
Citius Pharmaceuticals received a notice from Nasdaq stating its common stock has been below the $1.00 minimum bid price for 30 consecutive business days. The company has a compliance period until August 10, 2026, to regain compliance or face potential delisting.
🚩 Red Flags
- Delisting notice from Nasdaq due to sub-$1.00 share price.
- Potential requirement for a reverse stock split to maintain listing in the future.
📋 Key Facts
- Nasdaq notified the Company on February 9, 2026, regarding a violation of Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule).
- The company has a 180-day compliance period ending August 10, 2026.
- To regain compliance in a second 180-day window, the company may need to effect a reverse stock split.
- The Company's common stock continues to trade on Nasdaq under symbol 'CTXR'.
Citius Pharmaceuticals issued an 8-K to announce the release of its full-year fiscal 2025 results of operations. The filing serves as a formal mechanism to furnish the year-end press release via Exhibit 99.1.
📋 Key Facts
- Report date: December 23, 2025
- The company announced full-year fiscal 2025 results of operations via press release.
- Press release is furnished as Exhibit 99.1 and is not considered 'filed' for purposes of Section 18 liability.
Citius Pharmaceuticals announced the commercial launch of LYMPHIR™ by its majority-owned subsidiary, Citius Oncology, for the treatment of cutaneous T-cell lymphoma. The company also updated its corporate presentation.
📋 Key Facts
- Subsidiary Citius Oncology (Nasdaq: CTOR) launched LYMPHIR™ (denileukin diftitox-cxdl).
- LYMPHIR™ is an IL-2 receptor-directed fusion protein approved by the FDA.
- Indication: Treatment of adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.
- Company updated its corporate presentation on December 1, 2025.
Citius Pharmaceuticals, Inc. filed an 8-K to provide notice of an updated Corporate Presentation posted on its website as of October 23, 2025.
📋 Key Facts
- The company released an updated Corporate Presentation (Exhibit 99.1) on October 23, 2025.
- The filing is made pursuant to Item 7.01 (Regulation FD Disclosure).
- The presentation is intended for informational purposes and is not deemed 'filed' for liability purposes under Section 18 of the Exchange Act.
Citius Pharmaceuticals, Inc. completed a registered direct offering of common stock and warrants to an institutional investor, raising approximately $6.0 million in gross proceeds. The funds are intended to support the commercial launch of LYMPHIR™ and general corporate purposes.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 7.4 million total warrants (including pre-funded and placement agent warrants).
- The offering price ($1.51) is relatively close to the warrant exercise prices, suggesting a structured deal often used by micro-caps needing immediate liquidity.
- Presence of 'cashless' exercise provisions for warrants.
📋 Key Facts
- Gross proceeds from the offering: approximately $6.0 million.
- Net proceeds expected: approximately $5.5 million after fees and expenses.
- Securities issued: 1,460,000 shares of common stock at $1.51 per share; pre-funded warrants to purchase up to 2,513,510 shares at $1.5099 per share; and warrants to purchase up to 3,973,510 shares with an exercise price of $1.40.
- Placement Agent: H.C. Wainwright and Co., LLC received a 7.0% cash fee plus reimbursement for legal/expenses and placement agent warrants (278,146 shares at $1.8875).
- Use of proceeds: Commercial launch of LYMPHIR™, milestone/regulatory payments, development initiatives, and general corporate purposes.
- Market restriction: 90-day standby period on issuing new securities; may issue 'at the market' (ATM) shares at or above $2.15 after 30 days.
Citius Pharmaceuticals, Inc. filed an 8-K to announce the issuance of a press release regarding its third quarter fiscal 2025 results of operations.
📋 Key Facts
- The filing was made on August 12, 2025.
- The report pertains to Item 2.02 (Results of Operations and Financial Condition).
- A press release dated August 12, 2025, is furnished as Exhibit 99.1.
Citius Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement. The company successfully maintained a closing price of $1.00 or greater for 10 consecutive trading days, resolving the previous delisting risk.
🚩 Red Flags
- The company was previously under threat of delisting due to low stock price (implied by the necessity of this filing).
📋 Key Facts
- Received written notice from Nasdaq on July 7, 2025, confirming compliance with Listing Rule 5550(a)(2).
- Compliance was achieved by maintaining a closing bid price of $1.00 or greater for 10 consecutive trading days (June 20, 2025 - July 3, 2025).
- Nasdaq has officially considered the compliance matter closed.
Citius Pharmaceuticals completed a registered direct offering on June 11, 2025, raising approximately $6.0 million in gross proceeds. The offering included common stock and significant warrant coverage to an institutional investor.
🚩 Red Flags
- Significant warrant overhang: The issuance of nearly 14 million total warrants (standard and pre-funded) represents substantial potential dilution for existing shareholders.
- Warrant exercise price ($1.00) is below the current offering price ($1.22), creating immediate downward pressure upon exercise.
- Pre-funded warrants allow for massive equity issuance at a nominal cost ($0.0001 per share).
📋 Key Facts
- Gross proceeds from the offering: approximately $6.0 million.
- Net proceeds expected: approximately $5,455,000 after fees and expenses.
- Issuance of 540,000 shares of common stock at $1.22 per share.
- Issuance of pre-funded warrants to purchase up to 4,380,000 shares at $1.2199 per share.
- Issuance of warrants to purchase up to 9,840,000 shares with an exercise price of $1.00 per share.
- H.C. Wainwright and Co., LLC acted as the exclusive placement agent with a 7.0% cash fee.
- The company is subject to a 60-day no-issuance period, with an exception for ATM offerings at or above $1.75 per share after 30 days.
Citius Pharmaceuticals has significantly increased its authorized share capital through a stockholder-approved amendment, raising the total authorized shares from 26 million to 260 million. Additionally, the company redeemed one share of Series A Preferred Stock for $100.
🚩 Red Flags
- Massive increase in authorized share capital (10x increase) typically signals intent for significant future equity dilution.
- Highly contentious vote with a large number of shares cast 'AGAINST' the amendment.
📋 Key Facts
- Authorized shares increased from 26,000,000 to 260,000,000.
- Authorized common shares increased from 16,000,000 to 250,000,000.
- One share of Series A Preferred Stock issued on April 17, 2025, was redeemed for $100.
- The amendment was approved at a Special Meeting held on June 9, 2025.
- Voting results: 547,138,179 shares 'FOR' and 457,549,494 shares 'AGAINST'.
Citius Pharmaceuticals issued a $1 million unsecured promissory note to Pagoda Resources, Inc., featuring a high 15% interest rate compounded monthly. Notably, the debt is personally guaranteed by the Company's Chairman and CEO, Leonard Mazur.
🚩 Red Flags
- High interest rate (15% compounded monthly) suggests expensive/distressed financing.
- Personal guaranty by the CEO indicates potential liquidity constraints or difficulty securing traditional institutional debt.
- Short-term maturity (6 months) creates near-term refinancing risk.
📋 Key Facts
- Issued an unsecured promissory note for $1,000,000 to Pagoda Resources, Inc. on June 2, 2025.
- Interest rate is 15.00% per annum, compounded monthly.
- Maturity date is December 2, 2025 (6-month term).
- The note is non-convertible into equity.
- Repayment is personally guaranteed by Leonard Mazur, Chairman and CEO.
Citius Pharmaceuticals received a notice from Nasdaq stating it is non-compliant with the $1.00 minimum bid price requirement. The company is ineligible for a standard compliance period because it executed a reverse stock split within the last year.
🚩 Red Flags
- Delisting notice from Nasdaq
- Ineligibility for compliance period due to recent reverse stock split (Red Flag Escalator)
- Imminent delisting date of June 9, 2025, if appeal is not filed.
📋 Key Facts
- Received determination letter from Nasdaq on May 29, 2025.
- Non-compliance due to closing bid price being below $1.00 for 33 consecutive business days (Nasdaq Rule 5550(a)(2)).
- Ineligible for a standard compliance period because the company effected a reverse stock split during the prior one-year period.
- The company intends to request an appeal by June 5, 2025, to stay delisting.
- If no hearing is requested, delisting is scheduled for June 9, 2025.
Citius Pharmaceuticals, Inc. filed an 8-K to announce the release of its second quarter fiscal 2025 results of operations via a press release.
📋 Key Facts
- Report date: May 14, 2025
- The filing announces the issuance of Q2 fiscal 2025 results of operations.
- Results are provided in Exhibit 99.1 (Press Release).
Citius Pharmaceuticals entered into a subscription agreement with its Chairman and CEO, Leonard Mazur, for the issuance of a single share of newly designated Series A Preferred Stock. This transaction is specifically designed to facilitate an massive increase in authorized common stock from 16 million to 250 million shares by providing concentrated voting power for the upcoming special meeting.
🚩 Red Flags
- Related-party transaction: The CEO is using a specialized security to control the outcome of a massive share authorization increase.
- Extreme dilution potential: Increasing authorized shares from 16M to 250M represents a massive expansion of the equity base, likely intended for future dilutive financing.
- Governance manipulation: Reducing quorum requirements and creating 'super-voting' preferred stock are aggressive measures to ensure management's agenda passes despite potentially low shareholder turnout.
📋 Key Facts
- Leonard Mazur (Chairman and CEO) purchased one share of Series A Preferred Stock for $100 on April 17, 2025.
- The Series A Preferred Stock carries 1,000,000,000 votes specifically for the purpose of approving an Authorized Share Increase.
- The company seeks to increase authorized common stock from 16,000,000 to 250,000,000 shares.
- Bylaws were amended on April 16, 2025, to reduce the required quorum for stockholder meetings from a majority to one-third (1/3) of voting power.
- The Series A Preferred Stock is non-convertible and has no rights to dividends or liquidation proceeds; it will be redeemed for $100 immediately after the vote results are announced.
Citius Oncology (a subsidiary of Citius Pharmaceuticals) has entered into a letter agreement with Eisai Co., Ltd. to restructure the payment schedule for milestone payments and development costs related to the LYMPHIR™ product license.
🚩 Red Flags
- Restructuring of debt/obligations suggests liquidity constraints or cash flow management issues regarding milestone payments.
- Significant upcoming cash outflows through December 2025 ($~14.3M total) may pressure working capital for a micro-cap entity.
📋 Key Facts
- The amendment was signed on March 28, 2025, regarding the License Agreement for E7777 (denileukin diftitox).
- Citius Oncology owes Eisai a total of approximately $14.3 million in milestone payments and development/inventory costs.
- The new payment schedule requires an aggregate of $2,535,317.77 to be paid by July 15, 2025.
- Subsequent monthly payments will include $2,350,000 installments, with a final payment of $2,197,892.07 due on or before December 15, 2025.
- The agreement includes interest at a rate of 2% per annum from the original due date through the actual payment date.
- The parties released each other from claims related to previous failure to pay, except for potential breaches of this new letter agreement.
Citius Pharmaceuticals, Inc. entered into a securities purchase agreement for a registered direct offering of 465,000 common shares and pre-funded warrants to an institutional investor. The net proceeds are intended to fund the commercial launch of LYMPHIR™ and general corporate purposes.
🚩 Red Flags
- Significant dilution potential due to the issuance of over 1.2 million pre-funded warrants which are exercisable at a nominal price ($0.0001).
- Small offering size ($1.735M net) suggests limited runway and ongoing need for capital.
- Beneficial ownership limitations (4.99% to 9.99%) suggest the investor is structured to avoid triggering large shareholder reporting thresholds.
📋 Key Facts
- Offering price: $1.15 per share; Pre-funded Warrants at $1.1499 per share.
- Total shares involved: 465,000 common shares and up to 1,274,131 pre-funded warrants.
- Net proceeds estimated at approximately $1.735 million after fees.
- H.C. Wainwright and Co., LLC acted as the exclusive placement agent with a 7.0% cash fee.
- Placement Agent Warrants issued to Wainwright for up to 121,739 shares at an exercise price of $1.4375.
- The offering closed on April 2, 2025.
Citius Pharmaceuticals held its 2025 annual meeting of stockholders on March 10, 2025. The results included the election of seven directors and the ratification of Wolf & Company, P.C. as independent auditors.
🚩 Red Flags
- Shareholders rejected the proposal to increase authorized shares from 26,000,000 to 260,000,000, indicating potential investor resistance to significant future dilution.
📋 Key Facts
- Seven members were elected to the Board of Directors for a one-year term: Leonard Mazur, Myron Holubiak, Suren Dutia, Dr. Eugene Holuka, Dennis M. McGrath, Robert Smith, and Carol Webb.
- Stockholders approved executive compensation on a non-binding advisory basis (Say-on-Pay).
- A proposal to amend Articles of Incorporation to increase authorized shares from 26M to 260M was NOT approved.
- Wolf & Company, P.C. was ratified as the independent registered public accounting firm for the fiscal year ending September 30, 2025.
Citius Pharmaceuticals issued an 8-K to announce the release of its first quarter fiscal 2025 results of operations. The filing serves as a formal mechanism to furnish the press release containing these financial results.
📋 Key Facts
- Report date: February 14, 2025
- Subject matter: Results of operations for the first quarter of fiscal 2025
- Exhibit 99.1 contains the full press release regarding quarterly performance
Citius Pharmaceuticals announced that its subsidiary, Citius Oncology, Inc., has received a permanent J-code from CMS for LYMPHIR™ (denileukin diftitox-cxdl). This regulatory milestone facilitates easier reimbursement and administration of the drug in clinical settings.
📋 Key Facts
- LYMPHIR™ (denileukin diftitox-cxdl) has been assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code by CMS.
- The announcement was made on February 6, 2025.
- The news pertains to the oncology-focused subsidiary, Citius Oncology, Inc.
Citius Pharmaceuticals, Inc. completed a registered direct offering of 743,496 shares and warrants at $4.035 per unit to institutional investors. The net proceeds from the approximately $2.98 million gross offering are intended for general corporate purposes, including clinical development and working capital.
🚩 Red Flags
- Dilution risk due to the issuance of common stock and warrants.
- Placement agent received warrants (52,045 shares) with an exercise price of $5.0438, indicating a premium over the offering price but still contributing to potential dilution.
📋 Key Facts
- Offering Type: Registered direct offering of 743,496 shares of common stock and warrants to purchase up to 743,496 shares.
- Pricing: Combined offering price of $4.035 per share/warrant unit.
- Warrants: Exercise price of $4.035; exercisable immediately; 5-year expiration term.
- Net Proceeds: Approximately $2.7 million after deducting fees and expenses.
- Placement Agent: H.C. Wainwright and Co., LLC (7.0% cash fee plus expense reimbursements).
- Lock-up/Restrictions: 30-day prohibition on issuing convertible securities; 1-year prohibition on floating-rate or equity line of credit agreements.
Citius Pharmaceuticals issued a press release regarding commercial launch preparations for its immunotherapy product, LYMPHIR™, intended for treating adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The filing serves as a formal announcement of progress toward the product's market entry.
📋 Key Facts
- Announcement date: January 7, 2025
- Product name: LYMPHIR™
- Indication: Relapsed or refractory cutaneous T-cell lymphoma (CTCL)
- Status: Significant progress in preparations for commercial launch
Citius Pharmaceuticals, Inc. filed an 8-K to announce the release of its full year fiscal 2024 results of operations via press release.
📋 Key Facts
- The filing is a standard announcement of full year fiscal 2024 financial results.
- Report date: December 27, 2024.
- Results are provided in an attached press release (Exhibit 99.1).
Citius Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement. The company successfully maintained a closing bid price of $1.00 or greater for 12 consecutive trading days, resolving the previous delisting risk.
🚩 Red Flags
- Previous non-compliance with Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price.
📋 Key Facts
- The Company received written notice from Nasdaq on December 18, 2024.
- Compliance was met via a 12-consecutive trading day period from November 26, 2024, to December 12, 2024.
- The closing bid price remained at $1.00 per share or greater during the required period.
- Nasdaq has officially considered the compliance matter closed.
Citius Pharmaceuticals, Inc. has implemented a 1-for-25 reverse stock split to regain compliance with the Nasdaq Capital Market's $1.00 minimum bid price requirement. The split became effective on November 25, 2024, and shares began trading on an adjusted basis on November 26, 2024.
🚩 Red Flags
- Reverse stock split (Red flag escalator)
- Delisting risk/Nasdaq compliance issue (Minimum bid price requirement)
📋 Key Facts
- Implemented a 1-for-25 reverse stock split of common stock.
- The primary purpose is to regain compliance with Nasdaq's $1.00 minimum bid price requirement.
- Total authorized shares decreased from 400,000,000 to 16,000,000.
- Effective date: November 25, 2024, at 5:00 p.m. ET.
- Fractional shares will be rounded up to the nearest whole share at the participant level.
- The split applies to common stock issuable upon exercise of outstanding warrants and stock options.
Citius Pharmaceuticals announced a productive Type C meeting with the FDA regarding its Phase 3 clinical trial of Mino-Lok for treating central line-associated or catheter-related bloodstream infections. The company discussed potential pathways to regulatory approval.
📋 Key Facts
- Held a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 25, 2024.
- The meeting focused on the Phase 3 clinical trial of Mino-Lok®.
- Discussion included the pathway to regulatory approval for treating central line-associated infections or catheter-related bloodstream infections.
Citius Pharmaceuticals, Inc. completed a registered direct offering of 12 million shares and 12 million warrants at a combined price of $0.25 per unit. The offering was intended to raise approximately $2.7 million in net proceeds for clinical development and working capital.
🚩 Red Flags
- Significant dilution: Issuance of 12 million new shares plus 12 million warrants at a very low price point ($0.25).
- Highly dilutive warrant structure: Warrants are exercisable immediately and expire in five years, creating significant overhang.
- Low share price context: The offering price of $0.25 suggests the company is operating in a highly distressed or penny stock valuation range.
📋 Key Facts
- Offered 12,000,000 shares of common stock and 12,000,000 warrants at a combined price of $0.25 per unit.
- Warrants have an exercise price of $0.25 and expire five years after issuance.
- Net proceeds to the Company are approximately $2.7 million after fees.
- H.C. Wainwright and Co., LLC acted as the exclusive placement agent, receiving a 7.0% cash fee plus expense reimbursements.
- The company issued 840,000 placement agent warrants to Wainwright with an exercise price of $0.3125 per share.
- The offering was conducted via a previously effective Form S-3 registration statement.
Citius Pharmaceuticals received a decision from a Nasdaq Hearings Panel granting an extension to maintain its listing on the Nasdaq Capital Market. The company must regain compliance with the $1.00 minimum bid price rule by December 3, 2024.
🚩 Red Flags
- Ongoing delisting risk: The company is under a strict deadline (Dec 3, 2024) to meet minimum bid price requirements.
- History of non-compliance: The company has been struggling with the Bid Price Rule since at least September 2023.
📋 Key Facts
- Nasdaq Hearings Panel granted a request to continue listing on The Nasdaq Capital Market as of November 6, 2024.
- The company must regain compliance with the Bid Price Rule (minimum $1.00 per share) by December 3, 2024.
- Previous delisting determination was issued on September 10, 2024, after failing to meet compliance by the extended deadline of September 9, 2024.
- A hearing before the Nasdaq Hearings Panel was held on October 29, 2024.
Citius Pharmaceuticals issued a press release regarding preliminary results from an ongoing Phase I clinical trial. The study evaluates the safety and efficacy of a combined regimen of pembrolizumab and LYMPHIR™ (E7777) in patients with recurrent solid tumors.
📋 Key Facts
- Preliminary results released on November 11, 2024.
- Trial is an investigator-initiated Phase I clinical trial.
- Focuses on a combined regimen of pembrolizumab and LYMPHIR™ (denileukin diftitox-cxdl or E7777).
- Target population: patients with recurrent solid tumors.
Citius Pharmaceuticals has extended the employment term for Executive Vice Chairman Myron Holubiak by one year to October 31, 2025. Additionally, the company approved a one-year extension for several warrants held by CEO Leonard Mazur and Mr. Holubiak.
🚩 Red Flags
- Related-party transaction: Warrants held by the CEO (Leonard Mazur) and Executive Vice Chairman (Myron Holubiak) were extended, delaying potential dilution or cash inflow.
- Low exercise price ($0.77) for a significant block of warrants relative to typical market valuations.
📋 Key Facts
- Myron Holubiak's employment agreement term extended from Oct 31, 2024, to Oct 31, 2025.
- Extension of Investor Warrants for 2,793,297 shares (exercise price $0.77) held by CEO Leonard Mazur and Myron Holubiak until Sept 27, 2025.
- Extension of Underwriter Warrants for 194,358 shares (exercise price $1.11875) until Sept 27, 2025.
- Potential cash proceeds from full exercise of all warrants is approximately $2.4 million.
Citius Pharmaceuticals announced a partial deferral of a milestone payment due from its subsidiary, Citius Oncology, Inc., to Dr. Reddy’s Laboratories SA. The payment was triggered by the FDA approval of LYMPHIR™ and was originally due on September 9, 2024.
🚩 Red Flags
- Deferral of milestone payments can sometimes indicate liquidity management issues, though here it is described as an agreement between parties rather than a default.
📋 Key Facts
- Milestone payment for LYMPHIR™ was triggered by FDA regulatory approval.
- The original due date for the milestone payment was September 9, 2024.
- Dr. Reddy’s Laboratories SA agreed to a partial deferral of the payment without penalty.
- Citius Pharmaceuticals, Inc. acts as a guarantor for Citius Oncology, Inc.'s obligations under the Asset Purchase Agreement dated September 1, 2021.
Citius Pharmaceuticals received a formal delisting determination letter from Nasdaq on September 10, 2024, due to failure to regain compliance with the $1.00 minimum bid price rule. The company intends to request a hearing before a Nasdaq Hearing Panel to seek an additional extension.
🚩 Red Flags
- Delisting notice from Nasdaq (Item 3.01).
- Failure to meet minimum bid price requirements despite previous extensions.
- Uncertainty regarding whether a Hearing Panel will grant an additional extension or if compliance can be achieved.
📋 Key Facts
- Nasdaq issued a delisting determination letter on September 10, 2024.
- The deficiency is based on the failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days (Bid Price Rule).
- The company was previously granted an extension through September 9, 2024, which has now expired.
- The company intends to request a hearing before a Nasdaq Hearing Panel, which will automatically stay the delisting action pending the outcome.
Citius Pharmaceuticals announced that its product LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology. This is a positive regulatory/clinical milestone for the company's oncology portfolio.
📋 Key Facts
- LYMPHIR™ was added to the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology on September 5, 2024.
- The announcement was made via a press release filed as Exhibit 99.1.
Citius Pharmaceuticals, Inc. completed a merger involving its subsidiary Citius Oncology, Inc., resulting in the parent company owning approximately 92.6% of the new entity. The filing details several post-merger agreements including shared services, registration rights for large blocks of shares, and a promissory note to the parent company.
🚩 Red Flags
- Significant registration rights (over 65M shares) could lead to future dilution or selling pressure.
- Promissory note creates a debt obligation of $3.8M triggered by a specific financing milestone ($10M).
- Complexity of the merger/reorganization structure involving Cayman Islands and Delaware entities.
📋 Key Facts
- Merger completed on August 12, 2024; Citius Pharma owns ~92.6% of Citius Oncology, Inc.
- Amended & Restated Shared Services Agreement established for management and scientific services.
- Registration Rights Agreement covers an aggregate of 65,627,262 shares held by Citius Pharma.
- A promissory note was issued to Citius Pharma for $3,800,111 (capital contribution) due upon a financing event of at least $10 million.
- Transfer of LYMPHIR trademark and FDA BLA/IND rights delayed from 5 days post-approval to 60 days post-closing.
Citius Pharmaceuticals, Inc. filed an 8-K to announce its results of operations for the second quarter of fiscal 2024. The filing serves as a formal notice that a press release containing these financial results was issued on August 12, 2024.
📋 Key Facts
- Report date: August 12, 2024
- Reporting period: Second quarter of fiscal 2024
- The filing is a standard announcement of earnings results via Exhibit 99.1.
Citius Pharmaceuticals announced that the U.S. FDA has approved LYMPHIR™ (denileukin diftitox-cxdl) for treating relapsed or refractory cutaneous T-cell lymphoma. This represents a significant regulatory milestone and commercialization catalyst for the company's product pipeline.
📋 Key Facts
- FDA approval granted for LYMPHIR™ (denileukin diftitox-cxdl).
- Indication: Treatment of relapsed or refractory cutaneous T-cell lymphoma after at least one prior systemic therapy.
- Approval date reported as August 8, 2024.
Citius Pharmaceuticals announced positive topline results from its pivotal Phase 3 clinical trial of Mino-Lok for the treatment of central line-associated infections (CLABSI) or catheter-related bloodstream infections (CRBSI). The announcement is a significant clinical milestone for the company's product pipeline.
📋 Key Facts
- Announced positive topline results from pivotal Phase 3 clinical trial of Mino-Lok.
- Trial target population: patients with central line-associated infections or catheter-related bloodstream infections.
- Filing date: May 21, 2024.
Citius Pharmaceuticals, Inc. filed an 8-K to announce the release of its results of operations for the second quarter of fiscal 2024.
📋 Key Facts
- The filing was made on May 14, 2024.
- The company issued a press release regarding Q2 2024 financial results (Exhibit 99.1).
- The report is filed pursuant to Item 2.02 of Form 8-K.
Citius Pharmaceuticals completed a registered direct offering of 21,428,574 shares and warrants at a combined price of $0.70 per unit. The offering closed on April 30, 2024, providing approximately $13.8 million in net proceeds to fund clinical development and working capital.
🚩 Red Flags
- Significant dilution: Issuance of over 21 million new shares represents substantial potential dilution for existing shareholders.
- Warrant overhang: The issuance of warrants (both to investors and placement agent) creates significant future dilutive pressure as they are exercisable at prices ($0.75 and $0.875) near or above the current offering price.
📋 Key Facts
- Offered 21,428,574 shares of common stock and warrants to purchase up to 21,428,574 shares.
- Combined offering price: $0.70 per share/warrant unit.
- Warrants exercise price: $0.75 per share; exercisable six months after issuance; expires five years after initial exercise date.
- Net proceeds to the Company: approximately $13.8 million (after fees and expenses).
- H.C. Wainwright and Co., LLC acted as exclusive placement agent with a 7.0% cash fee plus expense reimbursements.
- Placement agent warrants granted to H.C. Wainwright for up to 1,500,000 shares at an exercise price of $0.875 per share.
- The offering was conducted via a previously effective Form S-3 registration statement.
Citius Pharmaceuticals announced a one-year extension for the expiration date of warrants held by its CEO and EVP. The extension moves the deadline from April 5, 2024, to April 5, 2025.
🚩 Red Flags
- Related-party transaction: The extension directly benefits the CEO (Leonard Mazur) and an Executive Vice President, allowing them more time to exercise their options.
- Potential dilution: Full exercise of warrants would result in the issuance of over 1.5 million new shares.
📋 Key Facts
- Board approved a one-year extension for 'Investor Warrants' expiring April 5, 2025.
- Investor Warrants cover an aggregate of 1,294,498 shares at an exercise price of $1.42 per share.
- Placement Agent Warrants (240,130 warrants at $1.9313/share) were also extended to April 5, 2025.
- Investor Warrants are held by CEO Leonard Mazur and EVP Myron Holubiak.
- Full exercise of all warrants would result in approximately $2.3 million in cash proceeds for the Company.
Citius Pharmaceuticals announced that the FDA has accepted the resubmission of its Biologics License Application (BLA) for LYMPHIR™ to treat relapsed or refractory cutaneous T-cell lymphoma. The FDA has set a PDUFA target action date of August 13, 2024.
📋 Key Facts
- FDA accepted the resubmission of the BLA for LYMPHIR™ (denileukin diftitox).
- Target indication: adults with relapsed or refractory cutaneous T-cell lymphoma.
- PDUFA target action date is set for August 13, 2024.
Citius Pharmaceuticals received a formal extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement by September 9, 2024. The company also held its 2024 annual meeting of stockholders, electing seven board members and ratifying Wolf & Company, P.C. as independent auditors.
🚩 Red Flags
- Delisting risk: The company is currently non-compliant with Nasdaq's Bid Price Rule.
- Deadline pressure: Compliance must be achieved by September 9, 2024, or delisting proceedings will commence.
📋 Key Facts
- Nasdaq granted an extension to evidence compliance with the $1.00 Bid Price Rule through September 9, 2024.
- Compliance requires the stock to close at $1.00 or more for ten consecutive business days.
- Failure to regain compliance by the deadline will result in a delisting notice and potential appeal process.
- Seven members were elected to the Board of Directors for one-year terms expiring in 2025.
- Stockholders ratified Wolf & Company, P.C. as independent registered public accounting firm for FY ending Sept 30, 2024.
Citius Pharmaceuticals issued an 8-K to announce the release of its first quarter fiscal 2024 results. The filing serves as a formal notice that financial results were made public via press release on February 14, 2024.
📋 Key Facts
- The company announced its Q1 fiscal 2024 results on February 14, 2024.
- Results of operations and financial condition were disclosed via a press release (Exhibit 99.1).
- The filing was signed by Leonard Mazur, Chairman and CEO.
Citius Pharmaceuticals announced the resubmission of its Biologics License Application (BLA) to the FDA for LYMPHIR™ (denileukin diftitox). The application targets adults with relapsed or refractory cutaneous T-cell lymphoma.
📋 Key Facts
- Resubmitted BLA for LYMPHIR™ (denileukin diftitox) on February 14, 2024.
- Target indication: Adults with relapsed or refractory cutaneous T-cell lymphoma.
- Filing includes a press release as Exhibit 99.1.
Citius Pharmaceuticals, Inc. announced the nomination of pharmaceutical executive Robert J. Smith to its Board of Directors. The nomination is subject to shareholder approval at the upcoming annual meeting on March 12, 2024.
📋 Key Facts
- Nomination of Robert J. Smith to the Board of Directors.
- Nomination requires shareholder approval.
- Annual meeting scheduled for March 12, 2024.
Citius Pharmaceuticals announced the upcoming 2024 Annual Meeting of Stockholders scheduled for March 12, 2024. The filing establishes the record date and deadlines for stockholder proposals and director nominations.
📋 Key Facts
- Annual Meeting Date: March 12, 2024, at 8:00 a.m. EST.
- Record Date: Close of business on January 19, 2024.
- Deadline for Rule 14a-8 stockholder proposals/nominations: January 16, 2024.
- Deadline for non-Rule 14a-8 nominations/business per Bylaws: January 16, 2024.
- Universal Proxy Rule compliance: Stockholders soliciting proxies must provide notice within 10 calendar days of this report.
Citius Pharmaceuticals announced its full-year 2023 results of operations and provided a clinical update regarding the Phase 3 trial for Mino-Lok®.
📋 Key Facts
- Issued press release on January 2, 2024, announcing fiscal year 2023 results (Item 2.02).
- Announced completion of enrollment in the pivotal Phase 3 Trial of Mino-Lok®, an antibiotic lock solution for catheter-related bloodstream infections (Item 8.01).
- The clinical update pertains to a product intended to salvage catheters in patients with infections.